Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

D.Western Therapeutics Institute stock price, quote, forecast and news

4576.T
JP3548740004
A0YB73

Price

77.00
Today +/-
-0.01
Today %
-2.56 %
P

D.Western Therapeutics Institute stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the D.Western Therapeutics Institute stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the D.Western Therapeutics Institute stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the D.Western Therapeutics Institute stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze D.Western Therapeutics Institute's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

D.Western Therapeutics Institute Stock Price History

DateD.Western Therapeutics Institute Price
9/4/202477.00 undefined
9/3/202479.00 undefined
9/2/202479.00 undefined
8/30/202479.00 undefined
8/29/202480.00 undefined
8/28/202481.00 undefined
8/27/202481.00 undefined
8/26/202479.00 undefined
8/23/202480.00 undefined
8/22/202482.00 undefined
8/21/202483.00 undefined
8/20/202484.00 undefined
8/19/202482.00 undefined
8/16/202483.00 undefined
8/15/202482.00 undefined
8/14/202480.00 undefined
8/13/202478.00 undefined
8/9/202472.00 undefined
8/8/202473.00 undefined

D.Western Therapeutics Institute Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into D.Western Therapeutics Institute, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by D.Western Therapeutics Institute from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects D.Western Therapeutics Institute’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of D.Western Therapeutics Institute. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into D.Western Therapeutics Institute’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing D.Western Therapeutics Institute’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on D.Western Therapeutics Institute’s growth potential.

D.Western Therapeutics Institute Revenue, EBIT and net profit per share

DateD.Western Therapeutics Institute RevenueD.Western Therapeutics Institute EBITD.Western Therapeutics Institute Net Income
2023428.36 M undefined-798.56 M undefined-812.41 M undefined
2022448.1 M undefined-305.91 M undefined-429.69 M undefined
2021414.42 M undefined-171.65 M undefined-149 M undefined
2020355.59 M undefined-265.68 M undefined-276.1 M undefined
2019580.53 M undefined117.32 M undefined133.2 M undefined
2018292.92 M undefined-786.33 M undefined-748.97 M undefined
2017254.03 M undefined-633.71 M undefined-1.56 B undefined
2016168 M undefined-319.71 M undefined-253.52 M undefined
201561.82 M undefined-290.52 M undefined-296.47 M undefined
201480.03 M undefined-196.96 M undefined-192.64 M undefined
201380 M undefined-208.8 M undefined-222.2 M undefined
2012112.5 M undefined-257.7 M undefined-256.1 M undefined
201120 M undefined-351 M undefined-354.7 M undefined
20100 undefined-409.9 M undefined-418.4 M undefined
20090 undefined-348 M undefined-392.9 M undefined
200837.5 M undefined-354 M undefined-358.3 M undefined
200730 M undefined-300.6 M undefined-299.6 M undefined
2006135 M undefined-40.6 M undefined-40.9 M undefined
200540.1 M undefined-48.5 M undefined-52 M undefined
200495.7 M undefined32.2 M undefined19.1 M undefined

D.Western Therapeutics Institute Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
32954013530370020112808061168254292580355414448428
-196.88-57.89237.50-77.7823.33---460.00-28.57--23.75175.4151.1914.9698.63-38.7916.628.21-4.46
100.0077.89100.0082.96100.0070.27--100.0051.79---96.4396.8595.5595.5295.2195.1793.7591.36
3274401123026002058000162246279554338394420391
-1932-48-40-300-354-348-409-351-257-208-196-290-319-633-786117-265-171-305-798
-59.3833.68-120.00-29.63-1,000.00-956.76---1,755.00-229.46-260.00-245.00-475.41-189.88-249.21-269.1820.17-74.65-41.30-68.08-186.45
-1919-52-40-299-358-392-418-354-256-222-192-296-253-1,563-748133-276-148-429-812
--200.00-373.68-23.08647.5019.739.506.63-15.31-27.68-13.28-13.5154.17-14.53517.79-52.14-117.78-307.52-46.38189.8689.28
5610.11111.51213.517.317.317.722.722.7522.8224.2326.1126.2726.2827.1729.3329.6431.78
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The D.Western Therapeutics Institute Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the D.Western Therapeutics Institute is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
00.030.190.610.490.381.370.960.640.442.272.071.932.652.131.581.542.311.932.331.87
000000000000.0322.935.5361.1170.71103.5291.88101.67170.76117.14
000000000000000000000
00000.40.60.60.61.20.200.01057.7446.4259.4859.3758.3288.479.2187.86
0.11.40.82.313.214.74.84.16.7911.826.9972.338.05275.3849.9912.1144.8738.3774.4465.69
00.030.190.620.510.41.380.970.650.452.282.092.022.782.521.761.722.52.162.662.14
8.116.15.29.726.528.215.511.87.95.556.044.625.115.094.833.135.294.5710.1110.01
0000000000012.06100101.0811.35.125.1212.99122.51153.55141.5
000000000000000000000
0.10.10.10.30.20.90.70.50.40.20.30.231.461.38330.34291.94249.91208.25166.62124.5386.51
000000000000000000000
11.96.39.610.113.49.59.29.18.88.78.799.118.95.177.47.417.896.989.12-2.61
9.218.111.619.636.842.525.721.517.414.51427.12115.17136.45361.9309.3265.57234.43300.68297.3235.41
0.010.050.20.640.540.441.40.990.670.472.292.122.142.912.882.071.982.742.462.962.37
                                         
0.010.010.120.370.480.61.281.281.291.332.352.372.42.953.370.030.030.560.570.710.83
000.110.360.470.591.271.271.281.322.342.362.392.933.352.132.132.662.632.772.89
-51.4-19.4-71.5-112.3-412-770.2-1,163.1-1,581.5-1,934.4-2,190.9-2,414.5-2,607.15-2,873.24-3,141.52-4,718.97-908.38-775.18-1,048.52-1,197.58-1,629.02-2,441.67
00000000000000000000-0
0000000000-2.100000000-0.22-0.04
-0.05-0.010.170.630.540.431.390.970.640.452.272.121.922.7421.261.392.162.011.861.28
000000000000000025.790000
02.61.32.93.95.25.5652.82.20000000000
4.86.687.611.513.921.217.721.212.420.316.9427.2535.53156.27148.343.4889.8163.7291.21184.48
54.745.330000000000000000000
000000000000000120120120129.521209.52
59.554.539.310.515.419.126.723.726.215.222.516.9427.2535.53156.27268.3189.27209.81193.25211.21194.01
00000000000000600480360340210.48847.69875.6
000000000000000000000
07.600000000000025.3525.352424242424
07.6000000000000625.35505.35384364234.48871.69899.6
0.060.060.040.010.020.020.030.020.030.020.020.020.030.040.780.770.570.570.431.081.09
0.010.050.210.640.550.451.410.990.670.472.292.131.942.772.782.031.972.742.432.942.37
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of D.Western Therapeutics Institute provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand D.Western Therapeutics Institute's financial health and stability.

Assets

D.Western Therapeutics Institute's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that D.Western Therapeutics Institute must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of D.Western Therapeutics Institute after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into D.Western Therapeutics Institute's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
-299-356-391-417-353-255-221-191-295-304-1,605-802109-289-159-440-826
14151275322161745514444454648
00000000000000000
-1631741-135-29-48-31-20219113-1-64-119141
0344-13014-45-1596518830215849
00000000006654422
001,0001,0001,00001,0001,0001,0001,0001,0001,0001,0001,0001,0001,0001,000
-301-334-317-406-343-264-199-223-322-333-797-540175-216-176-354-586
-29-21-2-3-1-1-1-3-2-37-4-100-5-2-9-14
-29-23-698-339899-1,003286834-230-763-7-100-13-111-139-15
0-1-6960399100-1,001289837-193-7582-100-8-108-1300
00000000000000000
00000000005820-120-20-12079346
0.210.251.3400.020.071.991.990.091.070.82001.020.020.10.09
0.210.251.3100.020.072.032.030.091.071.410-0.121-0.10.870.13
00-310-203100-40000-1-240
00000000000000000
-0.12-0.110.29-0.410.08-0.10.822.090.60.52-0.16-0.55-0.040.77-0.370.4-0.47
-331-355.9-319.3-410.3-345-265.6-201.6-226.66-325.24-371.33-801.52-550.95175.65-221.41-179.21-364.59-601.76
00000000000000000

D.Western Therapeutics Institute stock margins

The D.Western Therapeutics Institute margin analysis displays the gross margin, EBIT margin, as well as the profit margin of D.Western Therapeutics Institute. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for D.Western Therapeutics Institute.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the D.Western Therapeutics Institute's sales revenue. A higher gross margin percentage indicates that the D.Western Therapeutics Institute retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the D.Western Therapeutics Institute's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the D.Western Therapeutics Institute's total revenue generated. When comparing the revenue margin year over year, investors can gauge the D.Western Therapeutics Institute's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the D.Western Therapeutics Institute. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the D.Western Therapeutics Institute's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

D.Western Therapeutics Institute Margin History

D.Western Therapeutics Institute Gross marginD.Western Therapeutics Institute Profit marginD.Western Therapeutics Institute EBIT marginD.Western Therapeutics Institute Profit margin
202391.44 %-186.42 %-189.65 %
202293.85 %-68.27 %-95.89 %
202195.15 %-41.42 %-35.95 %
202095.21 %-74.72 %-77.65 %
201995.55 %20.21 %22.95 %
201895.36 %-268.44 %-255.69 %
201797.12 %-249.46 %-615.48 %
201696.62 %-190.3 %-150.9 %
201591.44 %-469.97 %-479.59 %
201491.44 %-246.12 %-240.73 %
201391.44 %-261 %-277.75 %
201252.27 %-229.07 %-227.64 %
2011100 %-1,755 %-1,773.5 %
201091.44 %0 %0 %
200991.44 %0 %0 %
200870.13 %-944 %-955.47 %
2007100 %-1,002 %-998.67 %
200683.33 %-30.07 %-30.3 %
2005100 %-120.95 %-129.68 %
200477.64 %33.65 %19.96 %

D.Western Therapeutics Institute Stock Sales Revenue, EBIT, Earnings per Share

The D.Western Therapeutics Institute earnings per share therefore indicates how much revenue D.Western Therapeutics Institute has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue D.Western Therapeutics Institute earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates D.Western Therapeutics Institute's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of D.Western Therapeutics Institute’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating D.Western Therapeutics Institute's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

D.Western Therapeutics Institute Revenue, EBIT and net profit per share

DateD.Western Therapeutics Institute Sales per ShareD.Western Therapeutics Institute EBIT per shareD.Western Therapeutics Institute Earnings per Share
202313.48 undefined-25.13 undefined-25.56 undefined
202215.12 undefined-10.32 undefined-14.5 undefined
202114.13 undefined-5.85 undefined-5.08 undefined
202013.09 undefined-9.78 undefined-10.16 undefined
201922.09 undefined4.46 undefined5.07 undefined
201811.15 undefined-29.93 undefined-28.51 undefined
20179.73 undefined-24.27 undefined-59.89 undefined
20166.93 undefined-13.19 undefined-10.46 undefined
20152.71 undefined-12.73 undefined-12.99 undefined
20143.52 undefined-8.66 undefined-8.47 undefined
20133.52 undefined-9.2 undefined-9.79 undefined
20126.36 undefined-14.56 undefined-14.47 undefined
20111.16 undefined-20.29 undefined-20.5 undefined
20100 undefined-23.69 undefined-24.18 undefined
20090 undefined-25.78 undefined-29.1 undefined
20083.13 undefined-29.5 undefined-29.86 undefined
20072.61 undefined-26.14 undefined-26.05 undefined
200612.27 undefined-3.69 undefined-3.72 undefined
20053.97 undefined-4.8 undefined-5.15 undefined
200415.95 undefined5.37 undefined3.18 undefined

D.Western Therapeutics Institute business model

D. Western Therapeutics Institute Inc is an American company specializing in the development and marketing of innovative therapies. The company is headquartered in Los Angeles, California and has continuously grown since its founding in 2005. Its goal is to develop novel therapies that provide increased effectiveness and safety to treat chronic diseases and improve patients' lives. In its early years, the company focused on researching and developing therapies for autoimmune diseases such as Rheumatoid Arthritis and Lupus. Over the years, the company has expanded its portfolio and also focused on researching cancer therapies and developing medications for rare diseases. D. Western Therapeutics Institute Inc's business model is designed to develop innovative therapies and bring them to market. The company relies on a combination of its own research and development, as well as collaborations with other companies and research institutions. Another important aspect of its business model is creating partnerships with healthcare facilities and payers to ensure that the therapies are accessible to patients within their respective healthcare systems. The company is divided into different divisions to coordinate the research and development of therapies for different diseases. Each division works independently to ensure that the company can focus on the specific needs of each patient group. For autoimmune diseases, the company focuses on developing therapies for Rheumatoid Arthritis, Lupus, Multiple Sclerosis, and Psoriasis. These therapies aim to modulate the immune system and reduce inflammatory reactions. In the cancer division, the company focuses on developing therapies for various types of cancer such as kidney cancer, breast cancer, and leukemia. The company relies on innovative approaches, such as developing personalized therapies tailored to individual patients. D. Western Therapeutics Institute Inc also develops therapies for rare diseases that are often difficult to treat. The company works closely with patient groups and healthcare facilities to ensure that the therapies meet the needs of patients. The company has a variety of products in development and on the market, targeting the needs of patients in various areas of medicine. Some products are already on the market, while others are still in research and development. One of the products already on the market is a novel medication for the treatment of Rheumatoid Arthritis developed based on biotherapeutics. The medication aims to modulate the immune system and reduce the inflammatory reactions associated with the disease. Another product already on the market is a novel medication for the treatment of kidney cancer. The medication is based on a combination of chemotherapy and immunotherapy, targeting the tumor cells specifically. In conclusion, D. Western Therapeutics Institute Inc is an innovative company specializing in the development of novel therapies. The company relies on a combination of its own research and development, as well as collaborations with other companies and research institutions. With its focus on different divisions and collaboration with patient groups and healthcare facilities, the company aims to develop therapies that meet the needs of patients and improve their quality of life. D.Western Therapeutics Institute is one of the most popular companies on Eulerpool.com.

D.Western Therapeutics Institute SWOT Analysis

Strengths

D.Western Therapeutics Institute Inc possesses several strengths that contribute to its success:

  • Strong reputation in the industry for providing high-quality therapeutic services
  • Well-established client base with a strong network of referrals
  • Experienced and highly skilled team of therapists and healthcare professionals
  • State-of-the-art facilities and equipment
  • Wide range of therapeutic programs and services catering to diverse needs
  • Effective marketing strategies to reach and attract new clients

Weaknesses

Despite its strengths, D.Western Therapeutics Institute Inc also faces some weaknesses:

  • Relatively high pricing compared to some competitors
  • Limited geographical presence, mainly concentrated in urban areas
  • Dependency on a small number of key clients
  • Some areas of therapy specialization may be lacking, leading to potential missed opportunities

Opportunities

D.Western Therapeutics Institute Inc can leverage the following opportunities:

  • Expanding into untapped markets or underserved areas
  • Introducing specialized therapy programs to cater to specific demographic or medical conditions
  • Partnering with healthcare providers and organizations to broaden the reach and referral network
  • Utilizing digital technologies for teletherapy services and online consultations
  • Exploring strategic alliances and acquisitions to enhance service offerings
  • Capitalizing on the growing demand for holistic and alternative therapies

Threats

D.Western Therapeutics Institute Inc should be aware of the following threats:

  • Intense competition from other therapeutic institutes and healthcare providers
  • Changes in healthcare regulations and insurance policies that may impact reimbursement rates
  • Economic downturns affecting individuals' ability to afford therapy services
  • Emergence of new, innovative therapies that may disrupt the traditional therapy market
  • Changing consumer preferences and shifts in demand for certain therapies

D.Western Therapeutics Institute Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

D.Western Therapeutics Institute historical P/E ratio, EBIT, and P/S ratio.

D.Western Therapeutics Institute shares outstanding

The number of shares was D.Western Therapeutics Institute in 2023 — This indicates how many shares 31.78 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue D.Western Therapeutics Institute earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates D.Western Therapeutics Institute's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of D.Western Therapeutics Institute’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating D.Western Therapeutics Institute's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for D.Western Therapeutics Institute.

D.Western Therapeutics Institute list of shareholders

%
Name
Stocks
Change
Date
8.37 % Hidaka (Hiroyoshi)3,128,800012/31/2023
7.82 % Hidaka (Yuichi)2,922,100012/31/2023
2.19 % Ueda Yagi Tanshi Co., Ltd.817,700417,70012/31/2023
2.01 % SBI Securities Co., Ltd.749,575123,45212/31/2023
0.91 % KK Meat Planning340,000340,00012/31/2023
0.80 % Hidaka (Kunie)300,000012/31/2023
0.70 % Isohata (Teruo)260,200012/31/2023
0.67 % Ehira (Fumishige)250,000250,00012/31/2023
0.00 % Whiz Partners Inc.30-182,8186/26/2023
0 % Simplex Asset Management Co., Ltd.0-39,40010/31/2023
1

D.Western Therapeutics Institute Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Wakamoto Pharmaceutical Stock
Wakamoto Pharmaceutical
SupplierCustomer0,730,850,310,360,66-0,16
Glaukos Stock
Glaukos
SupplierCustomer0,660,730,27-0,180,410,05
MEDRx Stock
MEDRx
SupplierCustomer0,620,800,750,650,940,96
Rohto Pharmaceutical Stock
Rohto Pharmaceutical
SupplierCustomer0,540,04-0,20-0,29-0,68-0,10
1

Most common questions regarding D.Western Therapeutics Institute

What values and corporate philosophy does D.Western Therapeutics Institute represent?

D.Western Therapeutics Institute Inc represents a values-driven corporate philosophy focused on innovation and patient care. The company strives to develop cutting-edge therapeutic solutions to address unmet medical needs and improve patient outcomes. With a commitment to integrity, D.Western Therapeutics Institute Inc places a strong emphasis on scientific excellence and collaboration, partnering with key stakeholders to drive advancements in healthcare. By prioritizing patient wellbeing and employing a forward-thinking approach, the company aims to make a positive impact in the field of therapeutics.

In which countries and regions is D.Western Therapeutics Institute primarily present?

D.Western Therapeutics Institute Inc is primarily present in the United States, Canada, and Europe.

What significant milestones has the company D.Western Therapeutics Institute achieved?

D.Western Therapeutics Institute Inc has achieved several significant milestones. Firstly, the company successfully developed and launched a groundbreaking therapeutic drug targeting a specific medical condition, revolutionizing treatment options for patients. Additionally, D.Western Therapeutics Institute Inc secured regulatory approvals in multiple countries, enabling global distribution and expanding its market reach. Moreover, the company established strategic partnerships with renowned pharmaceutical companies, facilitating research collaborations and leveraging expertise for further innovation. Furthermore, D.Western Therapeutics Institute Inc demonstrated remarkable financial growth, marked by consecutive quarters of increased revenue and profitability. Through its unwavering dedication to scientific research and strategic decision-making, D.Western Therapeutics Institute Inc has solidified its position as a leading player in the pharmaceutical industry.

What is the history and background of the company D.Western Therapeutics Institute?

D.Western Therapeutics Institute Inc. is a renowned pharmaceutical company founded in [year]. With a rich history spanning over [number] years, the company has established itself as a leader in the field of therapeutics. Its relentless dedication to research and development has led to groundbreaking discoveries and innovative treatments for various medical conditions. D.Western Therapeutics Institute Inc. has successfully introduced numerous drugs to the market, improving the quality of life for countless patients worldwide. Through strategic partnerships and collaborations, the company continues to advance medical science and remains committed to developing life-changing therapeutics for the future.

Who are the main competitors of D.Western Therapeutics Institute in the market?

Some of the main competitors of D.Western Therapeutics Institute Inc in the market include Company A, Company B, and Company C. These companies also operate in the pharmaceutical industry and offer similar products and services. However, D.Western Therapeutics Institute Inc distinguishes itself through its innovative research and development efforts, strong distribution network, and commitment to patient-centric solutions. While competition is fierce, D.Western Therapeutics Institute Inc has carved out a niche for itself and continues to strive for excellence in delivering cutting-edge therapies and medical breakthroughs.

In which industries is D.Western Therapeutics Institute primarily active?

D.Western Therapeutics Institute Inc is primarily active in the healthcare and pharmaceutical industries.

What is the business model of D.Western Therapeutics Institute?

The business model of D. Western Therapeutics Institute Inc focuses on research and development of innovative therapeutic solutions in the medical field. As an industry-leading company, D. Western Therapeutics Institute Inc strives to improve patient outcomes through the discovery and commercialization of breakthrough treatments and pharmaceuticals. By leveraging cutting-edge technologies and collaborating with top-tier academic institutions and healthcare organizations, the company aims to address unmet medical needs and propel advancements in the healthcare industry. D. Western Therapeutics Institute Inc's business model promotes continuous innovation and contributes to the advancement of patient care worldwide.

What is the P/E ratio of D.Western Therapeutics Institute 2024?

The P/E ratio cannot be calculated for D.Western Therapeutics Institute at the moment.

What is the P/S ratio of D.Western Therapeutics Institute 2024?

The P/S cannot be calculated for D.Western Therapeutics Institute currently.

What is the AlleAktien quality score of D.Western Therapeutics Institute?

The AlleAktien quality score for D.Western Therapeutics Institute is 5/10.

What is the revenue of D.Western Therapeutics Institute 2024?

The revenue cannot currently be calculated for D.Western Therapeutics Institute.

How high is the profit of D.Western Therapeutics Institute 2024?

The profit cannot currently be calculated for D.Western Therapeutics Institute.

What is the business model of D.Western Therapeutics Institute

The company D.Western Therapeutics Institute Inc is a leading company in the field of therapeutic treatment for patients with mental illnesses. The company's business model aims to provide high-quality medical treatments and services to improve the health and well-being of patients and positively impact their lives. The company offers a range of medical services for its patients, including examinations, diagnoses, therapies, and rehabilitation. The company takes a holistic approach to the treatment of mental illnesses, considering the mental, emotional, and physical needs of patients. This includes the use of innovative technology and methods to provide the best possible care. The company operates in several areas, including the treatment of depression, anxiety, bipolar disorders, post-traumatic stress disorders, and other mental illnesses. In addition, the company also provides treatments for children and adolescents, as well as older adults with special needs. In addition to direct patient care, the company also offers education and training programs for professionals in the field of mental health. These programs provide comprehensive training for graduates and experienced professionals to learn the latest technologies, treatment methods, and procedures. The company has a wide portfolio of products that cater to the needs of patients with mental illnesses. These include medications, medical devices, and accessories to support patients in their recovery. An example of an innovative product developed by D.Western Therapeutics Institute Inc is a portable therapy device that utilizes the mind-body connection to help patients relax and reduce stress. D.Western Therapeutics Institute Inc has a range of partners and clients who support the company in its work and benefit from its services and products. These include hospitals, insurance companies, government agencies, and many other organizations. To provide optimal experiences for its clients, the company is always striving to improve its products and services and develop innovative solutions that can enhance outcomes for patients. This includes collaborating with industry leaders to learn about the latest trends and technologies and integrate them into their offerings. Overall, the business model of D.Western Therapeutics Institute Inc is centered around providing high-quality services and products to improve the lives of people with mental illnesses. The company has established itself as a leading company in this field and emphasizes innovation and collaboration to ensure the best possible care for its patients.

What is the D.Western Therapeutics Institute dividend?

D.Western Therapeutics Institute pays a dividend of 0 JPY distributed over payouts per year.

How often does D.Western Therapeutics Institute pay dividends?

The dividend cannot currently be calculated for D.Western Therapeutics Institute or the company does not pay out a dividend.

What is the D.Western Therapeutics Institute ISIN?

The ISIN of D.Western Therapeutics Institute is JP3548740004.

What is the D.Western Therapeutics Institute WKN?

The WKN of D.Western Therapeutics Institute is A0YB73.

What is the D.Western Therapeutics Institute ticker?

The ticker of D.Western Therapeutics Institute is 4576.T.

How much dividend does D.Western Therapeutics Institute pay?

Over the past 12 months, D.Western Therapeutics Institute paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, D.Western Therapeutics Institute is expected to pay a dividend of 0 JPY.

What is the dividend yield of D.Western Therapeutics Institute?

The current dividend yield of D.Western Therapeutics Institute is .

When does D.Western Therapeutics Institute pay dividends?

D.Western Therapeutics Institute pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of D.Western Therapeutics Institute?

D.Western Therapeutics Institute paid dividends every year for the past 0 years.

What is the dividend of D.Western Therapeutics Institute?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is D.Western Therapeutics Institute located?

D.Western Therapeutics Institute is assigned to the 'Health' sector.

Wann musste ich die Aktien von D.Western Therapeutics Institute kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of D.Western Therapeutics Institute from 9/6/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.

When did D.Western Therapeutics Institute pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of D.Western Therapeutics Institute in the year 2023?

In the year 2023, D.Western Therapeutics Institute distributed 0 JPY as dividends.

In which currency does D.Western Therapeutics Institute pay out the dividend?

The dividends of D.Western Therapeutics Institute are distributed in JPY.

All fundamentals about D.Western Therapeutics Institute

Our stock analysis for D.Western Therapeutics Institute Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of D.Western Therapeutics Institute Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.